Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
The phase III CONTACT-01 trial evaluated atezolizumab plus cabozantinib vs docetaxel in patients with metastatic NSCLC after they had received checkpoint inhibitor treatment and chemotherapy.